SPOTLIGHT REVIEW Targets for therapy in sarcomeric cardiomyopathies
نویسندگان
چکیده
Department of Medicine and Cellular and Molecular Medicine, University of Arizona, 1656 East Mabel Street, MRB 312, Tucson, AZ 85724-5217, USA; Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany; Department of Pharmacology, University of California, Davis, CA, USA; Center of Molecular Medicine and Applied Biophysics (CIMMBA), University of Florence, Florence, Italy; Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum, Regensburg, Germany; Experimental Therapeutics and Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Physiology, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands; and ICIN-Netherlands Heart Institute, Utrecht, the Netherlands
منابع مشابه
Targets for therapy in sarcomeric cardiomyopathies.
To date, no compounds or interventions exist that treat or prevent sarcomeric cardiomyopathies. Established therapies currently improve the outcome, but novel therapies may be able to more fundamentally affect the disease process and course. Investigations of the pathomechanisms are generating molecular insights that can be useful for the design of novel specific drugs suitable for clinical use...
متن کاملSPOTLIGHT REVIEW Research priorities in sarcomeric cardiomyopathies
Department of Physiology, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, van der Boechorststraat 7, 1081BT Amsterdam, The Netherlands; ICIN-Netherlands Heart Institute, Utrecht, The Netherlands; Brigham and Women’s Hospital, Cardiology, Boston, MA, USA; Department of Medicine and Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA; Referral Ce...
متن کاملGenetic advances in sarcomeric cardiomyopathies: state of the art
Genetic studies in the 1980s and 1990s led to landmark discoveries that sarcomere mutations cause both hypertrophic and dilated cardiomyopathies. Sarcomere mutations also likely play a role in more complex phenotypes and overlap cardiomyopathies with features of hypertrophy, dilation, diastolic abnormalities, and non-compaction. Identification of the genetic cause of these important conditions ...
متن کاملSarcomeric proteins and inherited cardiomyopathies.
Over the last two decades, a large number of mutations have been identified in sarcomeric proteins as a cause of hypertrophic, dilated or restrictive cardiomyopathy. Functional analyses of mutant proteins in vitro have revealed several important functional changes in sarcomeric proteins that might be primarily involved in the pathogenesis of each cardiomyopathy. Creation of transgenic or knock-...
متن کاملAnimal and in silico models for the study of sarcomeric cardiomyopathies.
Over the past decade, our understanding of cardiomyopathies has improved dramatically, due to improvements in screening and detection of gene defects in the human genome as well as a variety of novel animal models (mouse, zebrafish, and drosophila) and in silico computational models. These novel experimental tools have created a platform that is highly complementary to the naturally occurring c...
متن کامل